Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen

Journal of Allergy and Clinical Immunology

Volumn 133, Issue 1, 2014, Pages

  Patel, Piyush ^a,d   Holdich, Tom ^b   Fischer Von Weikersthal Drachenberg, Karl J ^c   Huber, Birgit ^c,e  

^a Allied Research International   (Canada)

^b Allergy Therapeutics   (United Kingdom)

^c Bencard Allergie GmbH   (Germany)

^d Inflamax Research   (Canada)

^e Amgen   (Canada)

Author keywords

Allergic rhinoconjunctivitis; environmental exposure chamber; ragweed; specific immunotherapy; ultrashort course

Indexed keywords

ANTIALLERGIC AGENT; PHOSPHORYL LIPID A; PLACEBO; POLLEN EXTRACT; SHORT RAGWEED POLLEN ALLERGOID ADSORBED LEVO TYROSINE MONOPHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOTHERAPY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; NAUSEA; NOSE OBSTRUCTION; PHASE 2 CLINICAL TRIAL; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RAGWEED; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; RHINORRHEA; SCORING SYSTEM; SKIN TEST; SNEEZING; SORE THROAT; SWELLING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT;

ADVERSE EVENT; AE; ALLERGIC RHINOCONJUNCTIVITIS; AR; EEC; ENVIRONMENTAL EXPOSURE CHAMBER; INTENTION TO TREAT; ITT; MONOPHOSPHORYL LIPID A; MPL; PER PROTOCOL; PP; RAGWEED; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; RQLQ; SAR; SEASONAL ALLERGIC RHINITIS; SIT; SPECIFIC IMMUNOTHERAPY; STANDARDIZED UNITS; SU; TOTAL SYMPTOM SCORE; TSS; ULTRASHORT COURSE;

ADOLESCENT; ADULT; AGED; ALLERGENS; AMBROSIA; ANTIGENS, PLANT; CLINICAL PROTOCOLS; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; LIPID A; MALE; MIDDLE AGED; PLANT EXTRACTS; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891737215     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.05.032     Document Type: Article

References (46)

1. R. Gupta, A. Sheikh, D.P. Strachan, and H.R. Anderson Burden of allergic disease in the UK: secondary analyses of national databases Clin Exp Allergy 34 2004 520 526
2. V. Bauchau, and S.R. Durham Prevalence and rate of diagnosis of allergic rhinitis in Europe Eur Respir J 24 2004 758 764
3. S.D. Reed, T.A. Lee, and D.C. McCrory The economic burden of allergic rhinitis: a critical evaluation of the literature Pharmacoeconomics 22 2004 345 361
4. J. Bousquet, P.J. Bousquet, P. Godard, and J.P. Daures The public health implications of asthma Bull World Health Organ 83 2005 548 554
5. H. Garn, and H. Renz Epidemiological and immunological evidence for the hygiene hypothesis Immunobiology 212 2007 441 452
6. G. Verlato, A. Corsico, S. Villani, I. Cerveri, E. Migliore, and S. Accordini et al. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study J Allergy Clin Immunol 111 2003 1232 1238
7. E.O. Meltzer, M.S. Blaiss, M.J. Derebery, T.A. Mahr, B.R. Gordon, and J.J. Sheth et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey J Allergy Clin Immunol 124 suppl 2009 S43 S70
8. J. Bousquet, C.P. van, and N. Khaltaev Allergic rhinitis and its impact on asthma J Allergy Clin Immunol 108 2001 S147 S334
9. J.L. Brozek, J. Bousquet, C.E. Baena-Cagnani, S. Bonini, G.W. Canonica, and T.B. Casale et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision J Allergy Clin Immunol 126 2010 466 477
10. C.A. Akdis, and K. Blaser Mechanisms of allergen-specific immunotherapy Allergy 55 2000 522 530
11. S.J. Till, J.N. Francis, K. Nouri-Aria, and S.R. Durham Mechanisms of immunotherapy J Allergy Clin Immunol 113 2004 1025 1034
12. J. Bousquet, R. Lockey, and H. Mallinhg Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper J Allergy Clin Immunol 102 1998 558 562
13. M.A. Calderon, B. Alves, M. Jacobson, B. Hurwitz, A. Sheikh, and S. Durham Allergen injection immunotherapy for seasonal allergic rhinitis Cochrane Database Syst Rev 2007 CD001936
14. P.M. Matricardi, P. Juna, V. Panetta, U. Wahn, and A. Narkus Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses J Allergy Clin Immunol 128 2011 791 799
15. L. Jacobsen, B. Niggemann, S. Dreborg, H.A. Ferdousi, S. Halken, and A. Høst et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study Allergy 62 2007 943 948
16. C. Möller, S. Dreborg, H.A. Ferdousi, S. Halken, A. Høst, and L. Jacobsen et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study) J Allergy Clin Immunol 109 2002 251 256
17. B. Niggemann, L. Jacobsen, S. Dreborg, H.A. Ferdousi, S. Halken, and A. Høst et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children Allergy 61 2006 855 859
18. P.A. Eng, M. Borer-Reinhold, I.A. Heijnen, and H.P. Gnehm Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood Allergy 61 2006 198 201
19. L. Cox, J.T. Li, H.S. Nelson, and R. Lockey Allergen immunotherapy: a practice parameter second update J Allergy Clin Immunol 120 suppl 2007 S25 S85
20. D.G. Marsh Studies on "allergoids" prepared from naturally occurring allergens Immunology 18 1970 705 722
21. A.W. Wheeler, D.M. Moran, B.E. Robins, and A. Driscoll L-tyrosine as an immunological adjuvant Int Arch Allergy Appl Immunol 69 1982 113 119
22. P. Patel, and A.M. Salapatek Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine Expert Rev Vaccines 5 2006 617 629
23. K.J. Drachenberg, A.W. Wheeler, P. Stuebner, and F. Horak A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections Allergy 56 2001 498 505
24. N. Mothes, M. Heinzkill, K.J. Drachenberg, W.R. Sperr, M.T. Krauth, and Y. Majlesi et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies Clin Exp Allergy 33 2003 1198 1208
25. P. Baldrick, D. Richardson, A.W. Wheeler, and S.R. Woroniecki Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy J Appl Toxicol 24 2004 261 268
26. L.M. DuBuske, A.J. Frew, F. Horak, P.K. Keith, C.J. Corrigan, and W. Aberer et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen Allergy Asthma Proc 32 2011 239 247
27. K.J. Drachenberg, M. Heinzkill, E. Urban, and S.R. Woroniecki Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents Allergol Immunopathol 31 2003 270 277
28. M. Rosewich, R.M. Shulze, K.J. Drachenberg, and S. Zielen Ultra-short course immunotherapy in children and adolescents during a 3 y-yrs post-marketing surveillance study Pediatr Allergy Immunol 21 2010 e185 e189
29. S. Zielen, D. Metz, E. Sommer, and H.-P. Scherf Short-term immunotherapy with allergoids and the adjuvant monophosphoryl lipid A Allergologie Jahrgang 30 suppl 2007 S1 S8
30. J. Day, F. Horak, M.P. Briscoe, S.M. Canonica, N. Fineman, and F. Krug et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper Clin Exp Allergy Rev 6 2006 31 59
31. Guidance for industry Allergic rhinitis: clinical development programs for drug products (draft guidance) 2000 US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Washington (DC)
32. A. Akerlund, M. Andersson, J. Leflein, T. Lildholdt, and N. Mygind Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication J Allergy Clin Immunol 115 suppl 2005 S460 S482
33. Sauve H, Patel P, Juniper EF, Talwar N. Development plan for an environmental exposure chamber (EEC) rhinoconjunctivitis quality of life questionnaire (RQLQ) in the EEC setting. Presented at XXV Congress of the European Academy of Allergology and Clinical Immunology, June 2006, Vienna, Austria.
34. R.G. Hamilton, and N.F. Adkinson Measurement of total and antigen-specific immunoglobulin G H.R. Rose, E.C. de Macario, J.L. Fahey, H. Friedman, G.M. Penn, Manual of clinical immunology 1992 American Society for Microbiology Washington (DC) 702 708
35. A. Salapatek, N. Camuso, A. Ahmed, and V. Nelson A retrospective analysis of anti-allergy drug efficacy tested in an environmental exposure chamber (EEC) model compared to that observed in the traditional allergy field trials demonstrates the clinical relevance of allergen exposure models [abstract] J Allergy Clin Immunol 129 2012 AB207
36. P. Devillier, M. Le Gall, and F. Horak The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy Allergy 66 2010 163 169
37. R. Dahl, A. Kapp, G. Colombo, J.G. de Monchy, S. Rak, and W. Emminger et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 118 2006 434 440
38. A. Didier, H. Malling, M. Worm, F. Horak, S. Jager, and A. Montaqut et al. Optimal dose, efficacy and safety of once daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis J Allergy Clin Immunol 120 2007 1338 1345
39. S.R. Durham, W.H. Yang, M.R. Pedersen, N. Johansen, and S. Rak Sublingual immunotherapy with once daily grass allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 117 2006 802 809
40. A. Bufe, P. Eberle, E. Franke-Beckmann, J. Funck, M. Kimmig, and L. Klimek et al. Safety and efficacy in children of an SQ standardised grass allergen tablet for sublingual immunotherapy J Allergy Clin Immunol 123 2009 167 173
41. H.S. Nelson, H. Nolte, P. Creticos, J. Maloney, J. Wu, and D.I. Bernstein Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults J Allergy Clin Immunol 127 2011 72 80
42. M. Blaiss, J. Maloney, H. Nolte, S. Gawchick, R. Yao, and D.P. Skoner Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents J Allergy Clin Immunol 127 2011 64 71
43. U. Wahn, A. Tabar, P. Kuna, S. Halken, A. Montagut, and O. de Beaumont et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis J Allergy Clin Immunol 123 2009 160 166
44. M.A. Calderon, D. Laranas, J. Kleine-Tebbe, L. Jacobsen, G. Passalacqua, and P.A. Eng et al. European Academy of Allergy and Clinical Immunology task force report on "dose-response relationship in allergen-specific immunotherapy" Eur J Allergy Clin Immunol 66 2011 1345 1359
45. U. Lehnigk, J. Kettner, D. Häfner, and A. Narkus Placeboeffekt in klinischen studien zur wirksamkeit subkutaner spezifischer immuntherapie (SIT) Allergo J 20 suppl 2011 S11 S12
46. H.B. Kaiser, P.K. Keith, T.B. Casale, and T. Holdich Significant reduction in combined symptom and medication score compared with placebo with a ragweed uSCIT formulation for seasonal pollen allergy J Allergy Clin Immunol 123 2009 731